Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy-Rituximab Combination in Burkitt's Leukemia and Lymphoma
NCT01290120Phase 2Completed
- Sponsor
- Northern Italy Leukemia Group
- Start
- Nov 2002
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Burkitt lymphoma (BL), B cell acute lymphoblastic leukemia (B-ALL), sponsored by Northern Italy Leukemia Group. Started Nov 2002; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT01290120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290120.